Skip to main content
OpenTrials
Completed

NCT Number: NCT03571724

A Study to Assess Changes in Cigarette Consumption During a Switch to Very Low Nicotine Cigarettes

This study evaluates the impact of switching from usual brand cigarettes to very low nicotine cigarettes on cigarette consumption, smoking behavior, and biomarkers of exposure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tobacco Use Behavior

Age range

26 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Celerion, Lincoln, Nebraska, United States

Loading trial locations.

About this study

Very low nicotine (VLN) cigarettes contain a 'non-additive' level of nicotine. This study will switch smokers from their usual brand to VLN cigarettes. Periodically during the study the investigators will collect blood and measure nicotine exposure and also other biomarkers to see what effect switching has. The participants will also use a diary to record number of cigarettes smoked. Cigarette butts will also be collected.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Potential subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study.

  • Is a healthy adult male or female adult smoker, 26 to 65 years of age, inclusive, at Screening.
  • Has been a smoker for at least 5 years prior to Screening. Brief periods of non smoking (e.g., up to 7 consecutive days due to illness, trying to quit, participation in a study where smoking was prohibited) during that time will be permitted at the discretion of the Investigator.
  • Reports smoking an average of 10 or more manufactured combustible cigarettes per day at Screening.
  • Usual brand (UB) of cigarette is a filtered king size cigarette (with an approximate length of 84 mm (± 3 mm)).
  • Has a positive urine cotinine (≥ 500 ng/ml) at Screening.
  • Has an exhaled Carbon Monoxide > 10 ppm at Screening.
  • If female, has a negative serum pregnancy test at Screening.
  • A female subject of childbearing potential must have been using one of the following forms of contraception and agree to continue using it through completion of the study:
  • hormonal (e.g., oral, vaginal ring, transdermal patch, implant, or injection) consistently for at least 3 months prior to Screening;
  • double barrier method (e.g., condom with spermicide, diaphragm with spermicide) consistently for at least 14 days prior to Screening;
  • intrauterine device for at least 3 months prior to Screening;
  • Essure® or similar nonsurgical sterilization procedure at least 6 months prior to Screening
  • a partner who has been vasectomized for at least 6 months prior to Screening;
  • abstinence beginning at least 14 days prior to Screening and through the End of Study.
  • A female subject of non childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to Screening:
  • hysteroscopic sterilization;
  • bilateral tubal ligation or bilateral salpingectomy;
  • hysterectomy;
  • bilateral oophorectomy; Or be postmenopausal with amenorrhea for at least 1 year prior to Day 1 and follicle stimulating hormone (FSH) levels consistent with postmenopausal status.
  • Willing to comply with the requirements of the study, including a willingness to use the test products.
  • Voluntary consent to participate in this study documented on the signed informed consent form (ICF).
  • Subject is not planning to leave the area during the course of the study.

Exclusion criteria

Subjects may be excluded from the study if there is evidence of any of the following criteria at Screening, start of Week -1 (first clinic visit), or during the study as noted, in the opinion of the Investigator.

  • History or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary (especially bronchospastic diseases and asthma), immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  • Clinically significant abnormal findings on the physical examination, medical history, ECG, or clinical laboratory results, in the opinion of the Investigator.
  • Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
  • An acute illness (e.g., upper respiratory infection, viral infection) requiring treatment with prescription medication(s) within 14 days prior to Screening or first clinic visit.
  • Fever (>100.5 degrees F) at Screening or first clinic visit.
  • Body mass index (BMI) greater than 40.0 kg/m2 or less than 18.0 kg/m2 at Screening.
  • History of drug or alcohol abuse or has used medical/recreational marijuana within 12 months of Screening.
  • Diabetes mellitus that is not controlled by diet/exercise alone, in the opinion of the Investigator.
  • Seated heart rate is lower than 40 bpm or higher than 99 bpm at Screening, unless deemed not clinically significant by the PI.
  • Seated systolic blood pressure <90 mmHg or >150 mmHg, diastolic blood pressure <40 mmHg or >95 mmHg at Screening, unless deemed not clinically significant by the PI.
  • Positive urine screen for drugs of abuse or alcohol at Screening or at the first clinic visit.
  • Female subjects who are pregnant, lactating, or intend to become pregnant from Screening through the End of Study.
  • Use of medications known to interact with cytochrome p450 2A6 (including, but not limited to, amiodarone, desipramine, isoniazid, ketoconazole, miconazole, phenobarbital, rifampin, tranylcypromine, methoxsalen) within 3 months prior to Screening and throughout the study.
  • Use of inhalers to treat any medical condition within 3 months prior to Screening and throughout the study.
  • Use of nicotine-containing products other than factory manufactured cigarettes [e.g., roll-your-own cigarettes, e-vapor products, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum] within 28 days prior to Screening.
  • Use of any prescription smoking cessation treatments, including, but not limited to, varenicline (Chantix®) or buproprion (Zyban®) within 3 months prior to Screening.
  • Self-reported puffer/non-inhaler (i.e., a smoker who draws smoke from the cigarette into the mouth and throat but does not inhale).
  • Planning to quit smoking during the study period or postponing a quit attempt in order to participate in the study.
  • Plasma donation within 7 days prior to Screening or at any time during the study.
  • Donation of blood or blood products (with the exception of plasma as noted above), had significant blood loss, or received whole blood or a blood product transfusion within 56 days prior to Screening.
  • Participation in a previous clinical study for an investigational drug, device, biologic, or tobacco product within 30 days prior to Screening.
  • Subject or a first-degree relative (i.e., parent, sibling, child) is a current or former employee of the tobacco industry or a named party or class representative in litigation with the tobacco industry.
  • Subject or a first-degree relative (i.e., parent, sibling, child) is a current employee of the clinic sites.

Treatment and study plan

Non-Menthol Very Low Nicotine Cigarettes

Other

King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco

Menthol Very Low Nicotine Cigarettes

Other

King size menthol cigarettes containing 0.4mg nicotine /g tobacco

Subject's UB non-mentholated filtered cigarettes

Other

King size non-menthol cigarettes

Subject's UB mentholated filtered cigarettes

Other

King size menthol cigarettes

Primary outcomes

  1. Cigarettes Per Day

    Time frame: Assessed daily from Week -1 to Week 6; Week -1, Week 2, and Week 6 reported

    Primary objective is to measure a change in cigarette consumption behavior before, during and after switching from usual brand to to VLN cigarettes. Subjects will record their cigarette consumption daily in an electronic diary. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).All 142 randomized subjects were included in the ITT population based on product use. Out of these, 71 subjects were included in the PP Population and 71 were excluded. All excluded subjects had a ratio of [plasma cotinine/CPD VLN]/[plasma cotinine/CPD baseline] > 0.2. It was pre-specified to exclude participants with a ratio >0.2 as they were considered non-compliant.

Secondary outcomes

  1. Biomarkers of Exposure - Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1 Butanol (NNAL)

    Time frame: -1 week, and at 2 and 6 weeks.

    Total 24 hour urine will be collected to evaluate changes in NNAL (4-methylnitrosamino)-1-3-pyridyl)-1-butanone biomarker) before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  2. Biomarkers of Exposure - Total N-Nitrosonornicotine (NNN)

    Time frame: -1 week, and at 2 and 6 weeks.

    Total 24 hour urine will be collected to evaluate changes in NNN before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  3. Biomarkers of Exposure - S-phenylmercapturic Acid (S-PMA)

    Time frame: -1 week, and at 2 and 6 weeks.

    Total 24 hour urine will be collected to evaluate changes in S-PMA (benzene biomarker) before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  4. Biomarkers of Exposure - 3-hydroxypropylmercapturic Acid (3-HPMA)

    Time frame: -1 week, and at 2 and 6 weeks.

    Total 24 hour urine will be collected to evaluate changes in 3-HPMA (acrolein biomarker) before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  5. Biomarkers of Exposure - 1-hydroxy Pyrene(1-OHP)

    Time frame: -1 week, and at 2 and 6 weeks.

    Total 24 hour urine will be collected to evaluate changes in 1-OHP before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  6. Biomarkers of Exposure - Total Nicotine Equivalents

    Time frame: -1 week, and at 2 and 6 weeks.

    Total 24 hour urine will be collected to evaluate changes in total nicotine equivalents before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  7. Biomarkers of Exposure - Carboxyhemoglobin (COHb)

    Time frame: Week -1, and at 2 and 6 weeks.

    Blood will be drawn to evaluate COHb before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  8. Biomarkers of Exposure -Cotinine

    Time frame: Week -1, and at 2 and 6 weeks.

    Blood will be drawn to evaluate cotinine levels before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment.

  9. Nicotine Pharmacokinetics - Maximum Nicotine Concentration (C-Max)

    Time frame: Week -1, and at 2 and 6 weeks.

    Blood samples will be drawn at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the start of cigarette smoking a single cigarette for determination of C-max at weeks -1, 2 and 6. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment.

  10. Nicotine Pharmacokinetics - Peak Nicotine Time (T-Max)

    Time frame: Week -1, and at 2 and 6 weeks.

    Blood samples will be drawn at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the start of cigarette smoking a single cigarette for determination of T-Max at weeks -1, 2 and 6. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment.

  11. Nicotine Pharmacokinetics - Area Under Nicotine Concentration Curve (AUC)

    Time frame: Week -1, and at 2 and 6 weeks.

    Blood samples will be drawn at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the start of cigarette smoking a single cigarette for determination of AUC at weeks -1, 2 and 6. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment.

  12. Smoking Topography - Puff Duration

    Time frame: -1 week, and at 2 and 6 weeks.

    Puff duration will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  13. Smoking Topography - Puff Volume

    Time frame: -1 week, and at 2 and 6 weeks.

    Puff volume will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  14. Smoking Topography - Peak Puff Flow Rate

    Time frame: -1 week, and at 2 and 6 weeks.

    Peak Puff Flow Rate will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  15. Smoking Topography - Average Flow Rate

    Time frame: -1 week, and at 2 and 6 weeks.

    Average Puff Flow Rate will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  16. Smoking Topography - Inter-puff Interval

    Time frame: -1 week, and at 2 and 6 weeks.

    Inter-puff interval will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  17. Subjective Effects -Fagerstrom Test for Cigarette Dependance (FTCD)

    Time frame: -1 week, and at 2, 4, and 6 weeks.

    Subjects will answer a Fagerstrom Test for Cigarette Dependance (FTCD) questionnaire which contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence.The Fagerstrom Test for Nicotine Dependence, is scored from 0 to 1 for yes/no items and 0 to 3 for multiple-choice items.The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the greater the patient's physical dependence on nicotine. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  18. Subjective Effects -Brief Questionnaire of Smoking Urges (QSU-Brief)

    Time frame: Week -1, and at 2, 4, and 6 weeks.

    Subjects will answer a Brief Questionnaire of Smoking Urges (QSU-Brief). QSU is on a scale of 1-7, with 1 being strongly disagree and 7 being strongly agree. The average score of the following is taken to determine the Factor Score 1 and Factor Score 2; Factor 1: Average of Questions 1, 3, 6, 7, and 10; Factor 2: Average of Questions 2, 4, 5, 8, and 9. The score for each factor is calculated by summing the item scores; the total score is calculated by summing all questions together. The higher the score, the greater the urge to smoke. The total score range for this questionnaire is 10-70. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  19. Subjective Effects - Minnesota Nicotine Withdrawal Scale - Revised (MNWS-R)

    Time frame: -1 week, and at 2, 4, and 6 weeks.

    Subjects will answer a MNWS-R questionnaire. The MNWS is considered as the briefest scale among the self-report measures of nicotine withdrawal symptoms currently available. The original MNWS was developed by Hughes and Hatsukami in 1986. It consisted of nine nicotine withdrawal symptoms including craving. The scale was modified to reflect changes made in the fourth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for nicotine withdrawal. The total score of the scale range from 0 to 36 depending on participant's rate for the symptoms as not present (0), slight (1), mild (2), moderate (3), and severe (4). A high total score implies high nicotine addiction. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

  20. Subjective Effects - Perceived Health Risks

    Time frame: -1 week, and at 2, 4, and 6 weeks.

    Subjects will answer a Perceived health risks questionnaire. The subjects indicated their perception of the risk of becoming addicted to the cigarette they were currently using on a scale from 1 to 10. Scale =1 was a very low risk of becoming addicted and Scale =10 was a very high risk of becoming addicted. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).

Sponsors and collaborators

Lead sponsor

22nd Century Group, Inc.

Industry

Collaborators

  • Celerion

Registry information

Official study title

A Longitudinal Ambulatory Study to Assess Changes in Cigarette Consumption and Biomarkers of Exposure During a 6-week Switch to Very Low Nicotine Cigarettes

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 28, 2018
Registry last updated
Sep 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.